The additional value of PET/CT over PET in FDG imaging of oesophageal cancer

Bar‐Shalom, Rachel; Guralnik, Ludmila; Tsalic, Medy; Leiderman, Max; Frenkel, Alex; Gaitini, Diana; Ben‐Nun, Alon; Keidar, Zohar; Israel, Ora

doi:10.1007/s00259-005-1795-y

Cited by 118 publications

(60 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The evaluation of LN metastasis using PET-CT fusion images improves the sensitivity, accuracy, and the negative predictive value (18). In one study, PET-CT could distinguish the FDG uptake by primary tumors and the FDG uptake by adjacent LNs in 64% of sites located in the proximity to the primary tumor, allowing the locoregional involvement to be accurately evaluated (19). In another study, among 28 metastatic LNs located in the vicinity of primary tumors, six were false negative according to PET and two were false-negative according to PET-CT (18).…”

Section: Discussionmentioning

confidence: 99%

Multidetector CT Assessment of Lymph Node Size for Nodal Staging in Patients with Potentially Operable Squamous Esophageal Cancer and the¹⁸F-FDG Positron Emission Tomography CT Correlation

Yoon

Jung

Park

et al. 2010

J Korean Soc Radiol

View full text Add to dashboard Cite

Purpose:To investigate the size criteria of multidetector computed tomography (MD-CT) for the evaluation metastatic lymph nodes (LNs) for potentially operable squamous esophageal cancer, and to compare this information with the results of positron emission tomography-CT (PET-CT). Materials and Methods: Twenty-four patients who underwent radical esophagectomy for esophageal cancer were studied. All patients had preoperative MDCT and PET-CT. The MDCT findings were compared with those of PET-CT and were correlated with the surgical records. The receiver operating characteristic (ROC) curve method was used to determine the appropriate cut-off value to distinguish benign from metastatic LNs. Results: The size of metastatic LNs (9.35 3.41 mm) was significantly larger than that of benign LNs (5.741.64 mm) (p<0.001). The best cut-off value was 7 mm (81.8% sensitivity, 80.8% specificity). PET-CT detected all metastatic LNs except for four in the peritumoral region. The sensitivity and specificity of metastatic LN evaluation on PET-CT were 82.6% and 99.4%, respectively. Only one LN without metastasis showed increased fluoro-2-deoxy-D-glucose uptake on PET-CT. Conclusion: Size of metastatic LNs can typically be < 10 mm. For MDCT, the short diameter of 7 mm may be the optimal criterion. PET-CT is very accurate for the assessment of metastatic LNs except for those in the peritumoral region.

show abstract

Section: Discussionmentioning

confidence: 99%

Multidetector CT Assessment of Lymph Node Size for Nodal Staging in Patients with Potentially Operable Squamous Esophageal Cancer and the¹⁸F-FDG Positron Emission Tomography CT Correlation

Yoon

Jung

Park

et al. 2010

J Korean Soc Radiol

View full text Add to dashboard Cite

show abstract

“…After the full text of the remaining studies was read, 35 articles were excluded because these concerned review studies (n 5 13), nondiagnostic studies (n 5 8), poster abstracts (n 5 5), publications in other than prespecified languages (n 5 4), case reports (n 5 2), a study that included fewer than 10 patients (n 5 1), or studies in which insufficient data were available (n 5 2). Missing data of these latter 2 studies were requested from study authors without satisfying result (15,16). Screening of references of these eligible articles and related review studies did not yield additional relevant publications.…”

Section: Eligible Studiesmentioning

confidence: 99%

Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

The aim of this study was to assess the diagnostic performance of 18 F-FDG PET and integrated 18 F-FDG PET/CT for diagnosing recurrent esophageal cancer after initial treatment with curative intent. Methods: The PubMed, Embase, and Cochrane library were systematically searched for all relevant literature using the key words " 18 F-FDG PET" and "esophageal cancer" and synonyms. Studies examining the diagnostic value of 18 F-FDG PET or integrated 18 F-FDG PET/CT, either in routine clinical follow-up or in symptomatic patients in whom recurrence of esophageal cancer was suspected, were deemed eligible for inclusion. The primary outcome was the presence of recurrent esophageal cancer as determined by histopathologic biopsy or clinical follow-up. Risk of bias and applicability concerns were assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Sensitivities and specificities of individual studies were meta-analyzed using bivariate randomeffects models. Results: Eight eligible studies were included for meta-analysis, comprising 486 patients with esophageal cancer who underwent 18 F-FDG PET or PET/CT after previous treatment with curative intent. The quality of the included studies assessed by the QUADAS-2 tool was considered reasonable; there were few concerns with regard to the risk of bias and applicability. Integrated 18 F-FDG PET/CT and standalone 18 F-FDG PET were used in 4 and 3 studies, respectively. One other study analyzed both modalities separately. In 4 studies, 18 F-FDG PET or PET/CT was performed as part of routine follow-up, whereas in 4 other studies the diagnostic test was performed on indication during clinical follow-up. Pooled estimates of sensitivity and specificity for 18 F-FDG PET and PET/CT in diagnosing recurrent esophageal cancer were 96% (95% confidence interval, 93%-97%) and 78% (95% confidence interval, 66%-86%), respectively. Subgroup analysis revealed no statistically significant difference in diagnostic accuracy according to type of PET scanner (standalone PET vs. integrated PET/CT) or indication of scanning (routine follow-up vs. on indication). Conclusion: 18 F-FDG PET and PET/CT are reliable imaging modalities with a high sensitivity and moderate specificity for detecting recurrent esophageal cancer after treatment with curative intent. The use of 18 F-FDG PET or PET/CT particularly allows for a minimal false-negative rate. However, histopathologic confirmation of 18 F-FDG PET-or PET/CTsuspected lesions remains required, because a considerable falsepositive rate is noticed.

show abstract

“…It also leads to a change of treatment more frequently when compared with PET alone or CT alone [8,9]. The superiority of combined PET/CT as against PET alone has been confi rmed in other cancers and in cancer screening [1,[3][4][5][6] as well.…”

mentioning

confidence: 99%

Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer

Sheen

et al. 2007

Ann Nucl Med

View full text Add to dashboard Cite

6.11% for aorta, 5.85% ± 4.99% for liver, 5.47% ± 6.81% for muscle, and 2.81% ± 3.05% for bone marrow, and those of SUV ave were 10.17% ± 9.00%, 10.51% ± 7.89%, 4.95% ± 3.89%, 5.66% ± 9.12%, and 2.49% ± 2.50%, respectively. The mean differences of SUV max between enhanced and nonenhanced PET/CT were 5.89% ± 3.92% for lung lesions (n = 41), 6.27% ± 3.79% for LNs (n = 76), and 3.55% ± 3.38% for metastatic lesions (n = 35), and those of SUV ave were 3.22% ± 3.01%, 2.86% ± 1.71%, and 2.33% ± 3.95%, respectively. Although one LN status changed from benign to malignant because of contrast-related artifact, there was no up-or downstaging in any of the patients after contrast enhancement. Conclusions An i.v. contrast agent may be used in PET/CT without producing any clinically signifi cant artifact.

show abstract

The additional value of PET/CT over PET in FDG imaging of oesophageal cancer

Abstract: PET/CT improves the accuracy of FDG imaging in oesophageal cancer and provides data of diagnostic and therapeutic significance for further patient management.

Cited by 118 publications

References 19 publications

Multidetector CT Assessment of Lymph Node Size for Nodal Staging in Patients with Potentially Operable Squamous Esophageal Cancer and the¹⁸F-FDG Positron Emission Tomography CT Correlation

Multidetector CT Assessment of Lymph Node Size for Nodal Staging in Patients with Potentially Operable Squamous Esophageal Cancer and the¹⁸F-FDG Positron Emission Tomography CT Correlation

Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis

Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer

Contact Info

Product

Resources

About

The additional value of PET/CT over PET in FDG imaging of oesophageal cancer

Abstract: PET/CT improves the accuracy of FDG imaging in oesophageal cancer and provides data of diagnostic and therapeutic significance for further patient management.

Cited by 118 publications

References 19 publications

Multidetector CT Assessment of Lymph Node Size for Nodal Staging in Patients with Potentially Operable Squamous Esophageal Cancer and the18F-FDG Positron Emission Tomography CT Correlation

Multidetector CT Assessment of Lymph Node Size for Nodal Staging in Patients with Potentially Operable Squamous Esophageal Cancer and the18F-FDG Positron Emission Tomography CT Correlation

Diagnostic Performance of 18F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis

Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer

Contact Info

Product

Resources

About

Multidetector CT Assessment of Lymph Node Size for Nodal Staging in Patients with Potentially Operable Squamous Esophageal Cancer and the¹⁸F-FDG Positron Emission Tomography CT Correlation

Multidetector CT Assessment of Lymph Node Size for Nodal Staging in Patients with Potentially Operable Squamous Esophageal Cancer and the¹⁸F-FDG Positron Emission Tomography CT Correlation

Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis